A 35-year-old woman from rural Maharashtra presents to the gynaecology clinic for cervical cancer screening. She is a multiparous woman (G5P5) with menarche at age 13 and first coitus at age 18. On speculum examination, the cervix appears normal. Pap smear is performed and cytology shows atypical squamous cells of undetermined significance (ASCUS). HPV testing is positive for high-risk HPV-16. What is the most appropriate next step in management?

Explanation

## Management of ASCUS with High-Risk HPV Positivity **Key Point:** ASCUS with high-risk HPV positivity is considered a significant finding that warrants colposcopic evaluation to exclude underlying cervical intraepithelial neoplasia (CIN) or malignancy. ### Risk Stratification ASCUS represents cytologic findings of uncertain clinical significance. The presence of high-risk HPV (particularly HPV-16) in this context elevates the risk of underlying CIN2+ from ~5% (HPV-negative ASCUS) to approximately 20–30% (HPV-positive ASCUS). ### Management Algorithm ```mermaid flowchart TD A[ASCUS on Pap smear]:::outcome --> B{HPV testing result?}:::decision B -->|HPV negative| C[Routine screening in 3 years]:::action B -->|HPV positive| D[Colposcopy with directed biopsy]:::action D --> E{Biopsy findings?}:::decision E -->|No CIN/Normal| F[Return to routine screening]:::action E -->|CIN1| G[Observation or LEEP based on age]:::action E -->|CIN2/3| H[LEEP or cold knife conization]:::action ``` ### Why Colposcopy? - **Direct visualization** of the transformation zone under magnification (10–40×) - **Identification of acetowhite lesions**, punctation, and mosaic patterns - **Tissue diagnosis** via targeted biopsy to grade any lesion present - **Sensitivity ~90%** for detecting CIN2+ when performed by trained providers **High-Yield:** HPV-positive ASCUS is NOT a reassuring finding—it mandates colposcopy. HPV-negative ASCUS can safely return to routine screening. ### Why Not the Other Options? - **Repeat Pap in 12 months:** Too conservative for HPV-positive ASCUS; delays diagnosis of CIN2/3 in ~20–30% of cases. - **LEEP without biopsy:** Premature treatment without tissue diagnosis; violates the principle of "see before you treat." - **Hysterectomy:** Inappropriate; reserved for completed childbearing, benign pathology, or advanced malignancy—not for screening-detected ASCUS. **Clinical Pearl:** In India, HPV-based screening (reflex HPV testing for ASCUS or primary HPV screening) is increasingly recommended over cytology-alone approaches due to superior sensitivity and negative predictive value [cite:FIGO Guidelines 2019]. [cite:ASCCP 2019 Consensus Guidelines]